Top Markets
#1 Black Phoenix Black Phoenix +21,533.52%
#2 Nesa Nesa +738.26%
#3 Kinesis Silver Kinesis Silver +54.95%
#4 BNB Attestation Service BNB Attestation Service +25.94%
#5 QuantixAI QuantixAI +23.16%
#6 EXOD EXOD +22.78%
#7 Biconomy Biconomy +20.22%
#8 Derive Derive +18.71%
#9 Zylo Ecosystem Zylo Ecosystem +16.31%
#10 Alchemist AI Alchemist AI +15.82%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Medigen Biotechnology Corp. Medigen Biotechnology Corp.

Medigen Biotechnology Corp.

3176
Rank in Stocks #19063
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated... Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
Share Price
$1.27
Market Cap
$176.31M
Change (1 day)
5.57%
Change (1 year)
29.36%
Country
TW
Trade Medigen Biotechnology Corp. (3176)

Category

Healthcare
Revenue for Medigen Biotechnology Corp. (3176)
Revenue in Aug 2026 TTM: 0
According to Medigen Biotechnology Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Medigen Biotechnology Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH